JANSSEN BIOTECH

TREMFYA® (guselkumab) is the first medication of its kind to be approved by the Food and Drug Administration (FDA) in 2017 to treat adults with moderate to severe plaque psoriasis. In July 2020, the FDA also approved TREMFYA® to treat adults with active psoriatic arthritis... In two medical studies, more than 5 out of 10 people who took TREMFYA® had at least a 20% improvement in active PsA symptoms (joint pain, stiffness, swelling) at 24 weeks compared to placebo. Individual results may vary.

Also known as: Janssen Biotech, Inc